Form 4: Director Receives 50,000 Shares as Compensation

Michael Jerman, a Director at Inhibitor Therapeutics, Inc., was issued 50,000 shares of common stock as compensation on May 4, 2026.

Summary

• Michael Jerman, a Director of Inhibitor Therapeutics, Inc., received 50,000 shares of common stock on May 4, 2026.
• These shares were issued as compensation under the Issuer's 2025 Equity Incentive Plan.
• Following this transaction, Mr. Jerman beneficially owns 180,411 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine compensation event for a director rather than significant financial or strategic news.

Positives

• Director compensation awarded in the form of equity, aligning management interests with shareholders.
• Issuance of 50,000 shares indicates continued investment in key personnel.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that equity-based compensation is a common practice in the biotechnology and pharmaceutical sectors to attract and retain talent, especially in growth-oriented companies like Inhibitor Therapeutics.

Stakeholder Impact

• Shareholders: The issuance of shares as compensation dilutes existing ownership slightly, but also aligns director incentives with long-term company performance.
• Employees: This action may signal a commitment to employee incentives through equity plans.
• Management: Reinforces the use of equity as a compensation tool for key personnel.

Key Dates

Keywords

Inhibitor Therapeutics, INTI, Form 4, SEC Filing, Director Compensation, Equity Incentive Plan, Common Stock